Jefferies Comments on Incyte's Presentation at the 2011 Global Healthcare Conference

According to a recent report, Incyte INCY presented at Jefferies 2011 Global Healthcare Conference and provided an positive update on potential ruxolitinib pricing. Additional topics discussed included the potential label on ruxolitinib, an update on the company's pricing strategy and highlights on the early stages of use of ruxolitinib. Jefferies maintains a Buy rating and $25.00 price target on Incyte. In the report, Jefferies said, "We remain confident in ruxolitinib approval and see significant upside on an approval and successful launch." Incyte closed yesterday at $17.21.